• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

低一氧化碳弥散能力、患者报告的指标以及甲襞毛细血管密度降低与系统性硬化症中的间质性肺疾病相关。

Low-Carbon Monoxide Diffusing Capacity, Patient-Reported Measures and Reduced Nailfold Capillary Density Are Associated with Interstitial Lung Disease in Systemic Sclerosis.

作者信息

De Angelis Rossella, Cipolletta Edoardo, Francioso Francesca, Carotti Marina, Farah Sonia, Giovagnoni Andrea, Salaffi Fausto

机构信息

Rheumatology Unit, Department of Clinical and Molecular Sciences, Polytechnic University of Marche, "Carlo Urbani" Hospital, Jesi, 60035 Ancona, Italy.

IRCCS INRCA, 60121 Ancona, Italy.

出版信息

J Pers Med. 2024 Jun 14;14(6):635. doi: 10.3390/jpm14060635.

DOI:10.3390/jpm14060635
PMID:38929856
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11205232/
Abstract

UNLABELLED

The aim of this paper is to identify factors associated with interstitial lung disease (ILD) in patients with systemic sclerosis (SSc) and build an algorithm to better define this association for a personalised application in clinical practice.

METHODS

A total of 78 SSc patients underwent HRCT to assess ILD. Demographic, clinical and laboratory variables were collected, focusing on those associated either directly or indirectly with lung involvement. The discriminant value of each variable was determined using the operating characteristic curves (ROC) and included in a model to estimate the strength of ILD association in SSc.

RESULTS

Thirty-three (42.31%) patients showed ILD on HRCT. DLco, M-Borg, GERD-Q and capillary density were significantly associated with the presence of ILD-SSc. A model including these variables had a coefficient of determination (R) of 0.697. DLco had an AUC of 0.861 ( < 0.001) with a cut-off of ≤72.3% (sensitivity 78.8%, specificity 91.1%, +LR 8.86). The m-Borg Scale showed an AUC of 0.883 ( < 0.001) with a cut-off >2 (sensitivity 84.8%, specificity 82.2%, +LR 4.77), GERD-Q had an AUC of 0.815 ( < 0.001) with a cut-off >7 (sensitivity 72.7%, specificity 86.7%, +LR 5.45). The capillary density showed an AUC of 0.815 ( < 0.001) with a cut-off of ≤4.78 (sensitivity 87.9%, specificity 68.9%, +LR 2.82). Based on the pre-test probability values, these four variables were applied to Fagan's nomogram to calculate the post-test probability of this association.

CONCLUSIONS

Our study identified four associated clinical factors of ILD in SSc patients. Moreover, their inclusion in an algorithm for the post-test probability, tailored to the specific patients' characteristics, significantly increases the ability to find out the presence of SSc-ILD.

摘要

未标注

本文旨在确定系统性硬化症(SSc)患者间质性肺疾病(ILD)的相关因素,并构建一种算法,以便在临床实践中更好地界定这种关联,实现个性化应用。

方法

共78例SSc患者接受了HRCT以评估ILD。收集了人口统计学、临床和实验室变量,重点关注那些直接或间接与肺部受累相关的变量。使用操作特征曲线(ROC)确定每个变量的判别值,并将其纳入一个模型,以估计SSc中ILD关联的强度。

结果

33例(42.31%)患者在HRCT上显示有ILD。DLco、M-博格量表、GERD-Q和毛细血管密度与ILD-SSc的存在显著相关。包含这些变量的模型的决定系数(R)为0.697。DLco的曲线下面积(AUC)为0.861(<0.001),截断值≤72.3%(敏感性78.8%,特异性91.1%,阳性似然比8.86)。M-博格量表的AUC为0.883(<0.001),截断值>2(敏感性84.8%,特异性82.2%,阳性似然比4.77),GERD-Q的AUC为0.815(<0.001),截断值>7(敏感性72.7%,特异性86.7%,阳性似然比5.45)。毛细血管密度的AUC为0.815(<0.001),截断值≤4.78(敏感性87.9%,特异性68.9%,阳性似然比2.82)。根据检验前概率值,将这四个变量应用于费根列线图,以计算这种关联的检验后概率。

结论

我们的研究确定了SSc患者中ILD的四个相关临床因素。此外,将它们纳入针对特定患者特征量身定制的检验后概率算法中,显著提高了发现SSc-ILD存在的能力。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2c70/11205232/7cba4901057b/jpm-14-00635-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2c70/11205232/fb46971e22f1/jpm-14-00635-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2c70/11205232/11835a27e07c/jpm-14-00635-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2c70/11205232/7cba4901057b/jpm-14-00635-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2c70/11205232/fb46971e22f1/jpm-14-00635-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2c70/11205232/11835a27e07c/jpm-14-00635-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2c70/11205232/7cba4901057b/jpm-14-00635-g003.jpg

相似文献

1
Low-Carbon Monoxide Diffusing Capacity, Patient-Reported Measures and Reduced Nailfold Capillary Density Are Associated with Interstitial Lung Disease in Systemic Sclerosis.低一氧化碳弥散能力、患者报告的指标以及甲襞毛细血管密度降低与系统性硬化症中的间质性肺疾病相关。
J Pers Med. 2024 Jun 14;14(6):635. doi: 10.3390/jpm14060635.
2
KL6 and IL-18 levels are negatively correlated with respiratory function tests and ILD extent assessed on HRCT in patients with systemic sclerosis-related interstitial lung disease (SSc-ILD).KL6 和 IL-18 水平与系统性硬化症相关间质性肺病(SSc-ILD)患者的呼吸功能测试和 HRCT 评估的间质性肺病程度呈负相关。
Semin Arthritis Rheum. 2024 Apr;65:152366. doi: 10.1016/j.semarthrit.2024.152366. Epub 2024 Jan 13.
3
Underdetection of Interstitial Lung Disease in Juvenile Systemic Sclerosis.间质性肺病在青少年系统性硬皮病中的漏诊。
Arthritis Care Res (Hoboken). 2022 Mar;74(3):364-370. doi: 10.1002/acr.24499. Epub 2022 Feb 17.
4
Determinants of impairment in lung diffusing capacity in patients with systemic sclerosis.系统性硬化症患者肺弥散功能受损的决定因素
Clin Exp Rheumatol. 2015 Jul-Aug;33(4 Suppl 91):S80-6. Epub 2015 Apr 16.
5
Performance of Forced Vital Capacity and Lung Diffusion Cutpoints for Associated Radiographic Interstitial Lung Disease in Systemic Sclerosis.用力肺活量和肺弥散切点在系统性硬化症相关间质性肺病中的表现。
J Rheumatol. 2018 Nov;45(11):1572-1576. doi: 10.3899/jrheum.171362. Epub 2018 Oct 1.
6
Predictors of lung function test severity and outcome in systemic sclerosis-associated interstitial lung disease.系统性硬化症相关间质性肺疾病肺功能测试严重程度及预后的预测因素
PLoS One. 2017 Aug 1;12(8):e0181692. doi: 10.1371/journal.pone.0181692. eCollection 2017.
7
Detection of interstitial lung disease in systemic sclerosis through partitioning of lung transfer for carbon monoxide.通过一氧化碳肺转移的分区检测系统性硬化症的间质性肺病。
Respiration. 2012;84(6):461-8. doi: 10.1159/000335473. Epub 2012 Jan 31.
8
Impact of Systemic Sclerosis-Associated Interstitial Lung Disease With and Without Pulmonary Hypertension on Survival: A Large Cohort Study of the German Network for Systemic Sclerosis.系统性硬化症相关间质性肺病伴或不伴肺动脉高压对生存的影响:德国系统性硬化症网络的一项大型队列研究。
Chest. 2024 Jan;165(1):132-145. doi: 10.1016/j.chest.2023.08.013. Epub 2023 Aug 13.
9
Ultrasound B-lines in the evaluation of interstitial lung disease in patients with systemic sclerosis: Cut-off point definition for the presence of significant pulmonary fibrosis.超声B线在系统性硬化症患者间质性肺疾病评估中的应用:显著肺纤维化存在的截断点定义
Medicine (Baltimore). 2018 May;97(18):e0566. doi: 10.1097/MD.0000000000010566.
10
Automatic Quantification of Interstitial Lung Disease From Chest Computed Tomography in Systemic Sclerosis.系统性硬化症中基于胸部计算机断层扫描的间质性肺疾病自动量化
Front Med (Lausanne). 2020 Sep 25;7:577739. doi: 10.3389/fmed.2020.577739. eCollection 2020.

本文引用的文献

1
Alveolar epithelial-to-mesenchymal transition in scleroderma interstitial lung disease: Technical challenges, available evidence and therapeutic perspectives.硬皮病间质性肺疾病中的肺泡上皮-间充质转化:技术挑战、现有证据及治疗前景
J Scleroderma Relat Disord. 2024 Feb;9(1):7-15. doi: 10.1177/23971983231181727. Epub 2023 Jun 20.
2
The identification and management of interstitial lung disease in systemic sclerosis: evidence-based European consensus statements.系统性硬化症中间质性肺疾病的识别与管理:基于证据的欧洲共识声明
Lancet Rheumatol. 2020 Feb;2(2):e71-e83. doi: 10.1016/S2665-9913(19)30144-4. Epub 2020 Jan 14.
3
Systemic sclerosis interstitial lung disease: unmet needs and potential solutions.
系统性硬皮病相关性间质性肺疾病:未满足的需求与潜在解决方案。
Nat Rev Rheumatol. 2024 Jan;20(1):21-32. doi: 10.1038/s41584-023-01044-x. Epub 2023 Nov 3.
4
Significant nailfold capillary loss and late capillaroscopic pattern are associated with pulmonary arterial hypertension in systemic sclerosis.显著的甲襞毛细血管缺失和晚期毛细血管镜图像与系统性硬化症相关的肺动脉高压相关。
Rheumatology (Oxford). 2024 May 3;63(6):1616-1623. doi: 10.1093/rheumatology/kead445.
5
Interstitial lung disease in patients with systemic sclerosis: what can we learn from the SENSCIS trial?系统性硬皮病患者的间质性肺病:我们能从 SENSCIS 试验中学到什么?
Clin Exp Rheumatol. 2023 Aug;41(8):1713-1719. doi: 10.55563/clinexprheumatol/trcv91. Epub 2023 Aug 3.
6
Expert consensus on the management of systemic sclerosis-associated interstitial lung disease.专家共识:系统性硬皮病相关间质性肺疾病的管理。
Respir Res. 2023 Jan 9;24(1):6. doi: 10.1186/s12931-022-02292-3.
7
Association of Symptoms of Gastroesophageal Reflux, Esophageal Dilation, and Progression of Systemic Sclerosis-Related Interstitial Lung Disease.胃食管反流症状、食管扩张与系统性硬化症相关间质性肺病进展的相关性。
Arthritis Care Res (Hoboken). 2023 Aug;75(8):1690-1697. doi: 10.1002/acr.25070. Epub 2023 Feb 7.
8
Differences in symptom experience among patients with systemic sclerosis: a cluster analytic approach to identifying subgroups.系统性硬皮病患者症状体验的差异:一种识别亚组的聚类分析方法。
Rheumatology (Oxford). 2023 Feb 6;62(SI):SI64-SI73. doi: 10.1093/rheumatology/keac444.
9
Assessment of disease outcome measures in systemic sclerosis.系统性硬化病的疾病结局评估。
Nat Rev Rheumatol. 2022 Sep;18(9):527-541. doi: 10.1038/s41584-022-00803-6. Epub 2022 Jul 20.
10
Detection and Monitoring of Interstitial Lung Disease in Patients with Systemic Sclerosis.系统性硬化症患者间质性肺病的检测和监测。
Curr Rheumatol Rep. 2022 May;24(5):166-173. doi: 10.1007/s11926-022-01067-5. Epub 2022 May 1.